A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study ID
NCT04845139
Status
Unknown

Conditions

  • Primary Central Nervous System Lymphoma
  • Refractory Central Nervous System Lymphoma
  • Relapsed Primary Central Nervous System Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Nivolumab given intraventricularly

Study Details

The purpose of this study is to determine whether Nivolumab given intrathecally is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Key Dates

First listed
Apr 14, 2021
Start date
Jul 2, 2022
Status verified
Jul 2022
Primary completion
Oct 30, 2022
Completion
Nov 30, 2022

Study Design

Enrollment
1 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab administration
    Nivolumab administration Q2W by intraventricular injection through Ommaya reservoir

Primary Outcome Measure

Adverse events [ Time Frame: On a continuous basis up to 1 month after the first dose of study drug ]

Related Studies